Latest News

Cutaneous lupus: Switching antimalarials can delay immunosuppressive therapy


 

EXPERT ANALYSIS FROM ICCLE 2018


Meanwhile, because of the risk of retinal toxicity with hydroxychloroquine, there’s been a shift in recent years from dosing up to 6.5 mg/kg per day of ideal body weight to a ceiling of 5 mg/kg per day of actual body weight (JAMA Ophthalmol. 2014 Dec;132[12]:1453-60), and a ceiling of 2.3 mg/kg per day actual body weight for chloroquine.

The idea was to prevent overdosing in people who are under their ideal body weight, but there have been concerns about the efficacy of the new dosing regimen in other patients. Dr. Fernandez has not seen evidence of this. “We do adhere to the new dosing recommendations” at the Cleveland Clinic, and “personally, I think we are seeing similar efficacy,” he said.

The most important risk factor for retinal toxicity is cumulative dose. The risk seems to be extremely low in the first 5 years, but increases afterwards. Most patients who develop retinal toxicity have taken a cumulative hydroxychloroquine dose of 1,000 g, equal to about 400 mg/d for 7 years. “The longer you are on the medicine, the higher your risk of developing retinal toxicity,” he noted.

Regardless of weight, it’s recommended to limit hydroxychloroquine to 400 mg daily and chloroquine to 250 mg daily, with a baseline ocular exam, and – barring any intervening problems – annual screening after 5 years.

Recommended Reading

VIDEO: Characteristic flora define intestinal microbiome in scleroderma
MDedge Rheumatology
VIDEO: Calming microglia might control fibromyalgia
MDedge Rheumatology
Newer IgG4 testing proving effective in assessing patients
MDedge Rheumatology
New agents may bring hope for SLE patients
MDedge Rheumatology
Caution crucial for stem cell transplant in scleroderma, despite potential interest
MDedge Rheumatology
Don’t trust interface dermatitis to diagnose dermatomyositis
MDedge Rheumatology
Median time to progression from discoid to systemic lupus may be less than a year
MDedge Rheumatology
Timely dermatomyositis diagnosis, treatment remain elusive
MDedge Rheumatology
Hydroxychloroquine throws off Quantiferon-TB Gold results, study finds
MDedge Rheumatology
Idiopathic pulmonary fibrosis a ‘robust diagnosis’
MDedge Rheumatology